左炔诺孕酮宫内缓释系统(曼月乐)治疗子宫腺肌病的临床疗效

Clinical Efficacy of Levonorgestrel Intrauterine System(Mirena) for the Treatment of Adenomyosis

目的研究左炔诺孕酮宫内缓释系统(曼月乐)治疗子宫腺肌病的临床疗效。方法选择2010年1月至2013年1月期间我院收治的120例子宫腺肌病患者为研究对象,随机分为给予左炔诺孕酮宫内缓释系统治疗的观察组60例和给予米非司酮治疗的对照组60例。观察两组的月经情况、子宫情况及CA125含量。结果治疗后,观察组的出血量(29.5±4.2)mL、NRS评分1.7±0.3、子宫内膜厚度(4.9±0.8)mm、子宫体积(217.3±29.8)cm3及CA125含量(19.3±2.5)μg/L,均明显低于对照组(P<0.05)。结论左炔诺孕酮宫内缓释系统治疗有助于改善月经情况、减小子宫体积和子宫内膜厚度、降低CA125含量,在子宫腺肌病的治疗中具有积极价值。

Objective To study the clinical efficacy of levonorgestrel intrauterine system （mirena） for the treatment of adenomyosis. Methods 120 patients with adenomyosis in our hospital from January 2010 to January 2013 were selected in this study, and randomly divided into observation group and control group, with 60 cases in each group. Patients in the observation group were treated with levonorgestrel intrauterine system （mirena）, while patients in the control group were treated with mifepristone. The menstruation, uterine conditions and CA125 levels were observed. Results In the observation group, the amount of bleeding was （29.5 ± 4.2） mL, NRS score was 1.7± 0.3, endometrial thickness was （4.9 ±0.8） mm, uterine volume was （217.3 ±29.8） cm3, and the CA125 levels was （19.3 ± 2.5）/zg/L; all the indices were significantly lower than those in the control group （P〈0.05）. Conclusions Levonorgestrel intrauterine system can help to improve menstruation situation, reduce uterine volume and endometrial thickness, and lower CA125 levels, which has positive value for the treatment of patients with adenomyosis.